Waning Protection from Vaccination Explains Rise in Mumps Cases

A study finds that the vaccine’s effects wear off as a person ages, suggesting a need for booster shots.

Written byCatherine Offord
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

US AIR FORCE, MATTHEW LOTZThe number of mumps cases has been increasing across the United States, a phenomenon that some researchers have suggested is due to evolution of the mumps virus to escape vaccination. But a more likely explanation is that vaccine-based protection against mumps wanes over a person’s lifetime, according to researchers at Harvard University. The findings, published yesterday (March 21) in Science, indicate a potential role for booster vaccines in maintaining protection throughout adulthood.

“Our results strongly support that the answer is waning vaccine-induced immunity, not a new vaccine-escape strain,” study coauthor Yonatan Grad, an infectious disease specialist at the Harvard T.H. Chan School of Public Health, tells The Philadelphia Inquirer.

Before the introduction of the mumps vaccine in 1967 in the U.S., more than 90 percent of children and adolescents came down with the infection. Although that percentage plummeted in the 1970s, the number of mumps infections saw spikes in the 1980s and 1990s, and again in 2006, particularly among young adults.

To understand the fluctuations, the Harvard researchers studied epidemiological data from a handful of studies carried out in Europe and in the U.S. between 1967 and 2008. The pair found that immunity from vaccination seems to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies